Transplant Diagnostics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Transplant Diagnostics Market is Segmented By Product Type (Instrument, Reagents & Consumables, Software, and Services), By Technology (Molecular Assay, Non-Molecular Assay), By Transplant Type (Solid Organ Transplantation, Bone Marrow Transplantation, Soft Tissue Transplantation), By Application (Pre-Transplant Diagnostics, Post-Transplant Diagnostics), By End-User (Hospitals and transplants centers, Diagnostic Laboratories, Research laboratories, and academic institutes, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030 

Transplant Diagnostics Market Overview

The Global Transplant Diagnostics Market report analyzes the global market size, shares, recent trends, competitive intelligence, and future market outlook. Transplant diagnostics involves the testing and analysis of donor and recipient compatibility in organ and tissue transplantation. In the Asia Pacific region, the Global Transplant Diagnostics Market is witnessing significant growth. Key players in the market include Thermo Fisher Scientific Inc., Illumina, Inc., bioMérieux SA,

Histocompatibility and immunogenetics of organ and hematopoietic stem cell transplants are based on transplant diagnostics. They aid healthcare practitioners in identifying whether possible organ donors and recipients are compatible. They improve organ survival while lowering the risk of significant transplant complications. As a result, they're used in various fields, including pathology, immunogenetics, infectious illnesses, molecular diagnostics, therapeutic medication monitoring, and HLA typing and monitoring.

Transplant Diagnostics Market Summary and Scope

For more insights - Download the Sample

Transplant Diagnostics Market Dynamics and Trends

Nucleic acid biomarkers to assess graft injury after liver transplantation is expected to drive market growth.

Ischemia-reperfusion damage, acute rejection, and primary graft malfunction are just a few of the risk factors and problems that might affect the success of a liver transplant. Molecular biomarkers can diagnose, predict, and track the evolution of damage or organ failure with great accuracy. There is a major opportunity for reliable and non-invasive biomarkers to minimize organ shortage by enabling donor organ quality assessment, short- and long-term graft function monitoring, and acute and chronic disease prediction. Moreover, High-throughput technologies allow vast amounts of data and information to be generated at many molecular levels. Recent multi-omics research has revealed distinct molecular fingerprints that provide substantially more information than the microscopy and staining procedures typically employed in medical diagnostics.

Additionally, Nucleic acids (such as microRNAs [miRNAs] and cell-free DNA), epigenetic patterns (such as DNA methylation and histone modifications), and more typical protein-based markers (such as glycoproteins, antigens, and antibodies) are all examples of molecular biomarkers. Proteomic and metabolomic biomarkers are less common markers that are investigated utilizing multi-analyte technologies that examine the entire collection of proteins or metabolites in a biological sample. Thus, the market segment is expected to drive in the forecast period from the above statements.

COVID-19 Impact on Transplant Diagnostics Market Growth

The COVID-19 pandemic has moderately impacted healthcare systems and the market. COVID-19 can be acquired by organ donation with a low risk of infection. COVID-19 symptoms and exposure history are checked on donors. Living donors who have been to high-risk locations or been exposed to someone who has been diagnosed or is being evaluated for COVID-19 infection are normally asked to wait 14 to 28 days before donating. COVID-19 testing is being done by some organ procurement organizations on some or all donors.

Moreover, Post-transplant or other high-risk patients may be at higher risk for severe disease from COVID-19 because transplant recipients are at a higher risk of infection from viruses such as the cold or flu and are on immunosuppressive medicines. To reduce the risk of contracting the COVID-19 coronavirus. Additionally, there were no transplants performed due to the ban on their transportation. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Transplant Diagnostics Market Segment and Shares

The molecular Assay segment is expected to hold the largest market share in the transplant diagnostics market

The molecular assay segment is expected to dominate in 2020. The segment growth is attributed because clinicians over molecular testing prefer Non-molecular assays. Also, serologic detection preferences for HLA typing are gradually shifting due to advantages such as accuracy, efficacy, and minimal risk. For diverse applications, PCR-based assays now have the biggest market share. For instance, in cfDNA analysis, several methodologies have been proposed, including real-time PCR, digital PCR, and next-generation sequencing-based approaches. A unique pilot set of tests targeting single-nucleotide polymorphisms with a high potential to identify cfDNA from two individuals to refine the droplet digital PCR (ddPCR)-based technique to measure relative dd-cfDNA in plasma from kidney transplant (KTx) patients. When assessing 165 ng of human DNA, the assays can accurately quantify minor allele content down to 0.1 percent. Therefore it has increased the demand for molecular assay, due to which the market segment is expected to hold the largest market share in the forecast period.

Transplant Diagnostics Market Geographical Analysis

North America region holds the largest market share in the global transplant diagnostics market

In 2020, North America accounted for the highest revenue share. The increasing prevalence of transplants, a well-developed research infrastructure, rising healthcare spending, widespread use of new diagnostic techniques, expanding R&D activities, and government participation in raising funds and raising awareness to promote organ transplantation for patients in the region are some of the factors due to which the market is expected to boost in the forecast period. For instance, More than 20,000 stem cell transplants are performed annually for hematologic malignancies in the United States. Of these transplants, approximately 60 percent are allogeneic, and 40 percent are autologous. Moreover, 17 people die each day waiting for an organ transplant, and 40,000+ transplants were performed in 2021. The incidence of kidney failure requiring dialysis or transplantation for end-stage renal disease (ESRD) in the U.S. ranks among the highest in the world. There are 24,670 kidney transplants performed in the U.S., and 90,483 transplant cases are on the waiting list.

Additionally, firms, such as Roche's collaboration with various hospitals, and organizations like the American Transplant Foundation, are implementing multiple initiatives and awareness programs to increase the number of organ donors. These businesses are pioneering the development of novel solutions for speedier disease diagnosis before and after transplantation, which private groups and governments have well received in the United States and Canada. Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Transplant Diagnostics Companies and Competitive Landscape

Major key players in the transplant diagnostics market are Abbott Laboratories, Biomérieux SA, Thermo Fisher Scientific Inc., Bio-Rad Laboratories, Inc., QIAGEN N.V., Immucor, Inc., Hologic, Inc., Biogenuix, and GenDx.

Thermo Fisher Scientific:

Overview:

Thermo Fisher Scientific is an American company incorporated in 1956 and is based in Waltham, Massachusetts. The company offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and services worldwide. Moreover, the global team has more than 90,000 colleagues who deliver an unrivaled combination of innovative technologies, purchasing convenience, and pharmaceutical services through industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, and Patheon.

­Product Portfolio:

AllType NGS Assays: AllType assays offer a complete next-generation sequencing solution that provides single-tube amplification for all eleven Class I and Class II loci, completely removing the need for amplicon pooling. Samples are transferred directly to the library preparation and ready for sequencing in a single workday. TypeStream Visual NGS Analysis Software automatically generates sequencing analysis and individual allele assignments. Results are delivered in fewer than three days.